Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- LDP Proposal for New Growth Strategy to Push “Clinical Innovation Network”
April 15, 2016
- New Scheme on Switch OTC Gets Underway
April 14, 2016
- MHLW to Issue Notification to Ensure Restricted Use of Repatha
April 14, 2016
- Indication-Based Front-Loaded Re-Pricing, Coverage Limits Emerge for Pricey Meds: Chuikyo
April 14, 2016
- Chuikyo to Make Go or No-Go Decision on Drug Price Survey by Mid-2016
April 14, 2016
- MHLW Panels Approve Guidelines for Reporting Adverse Reactions to Hep B Vaccines
April 14, 2016
- Govt, Industry Agree to Boost Public-Private Policy “Dialogue” to Deepen Talks on Social Security Challenges
April 13, 2016
- Chuikyo OKs Repatha for NHI Price Listing on April 20, Peak Sales Projected at 49 Billion Yen
April 13, 2016
- MHLW Advisory Panel to Discuss Ono’s Cancer Drug Carfilzomib on April 25
April 12, 2016
- With Eyes on Pricey Meds, Cost-Shaving Debate Unabated Despite Likely Tax Hike Delay
April 11, 2016
- Centralized Support Unit Needed for “Clinical Innovation Network”: JPMA’s Teshirogi
April 8, 2016
- PMDA to Set Up Hokuriku Branch to Train Asian Regulators
April 8, 2016
- Editor’s Pick: Five Healthcare Policy News Headlines for March
April 8, 2016
- MHLW Advisory Panel to Discuss Nobelpharma’s Epilepsy Drug on April 20
April 8, 2016
- NCCHD Aims to Build “Million-Person Database” on Pediatric Patients; Could Lead to Improvements in Pharmacotherapy
April 6, 2016
- Govt OKs Action Plan on Drug Resistance
April 6, 2016
- MEXT to Set Up “Shared Facilities” for Drug Discovery, Push Open Innovation
April 5, 2016
- MOF Panel Hears Expert’s Opinions on Opdivo Prices
April 5, 2016
- Key Govt Panel Kicks Off Discussions on Economic, Fiscal Policy Blueprint
April 5, 2016
- Govt Aims to Reduce Use of Antimicrobials by 33% by FY2020 as Part of Efforts to Fight Resistance
April 5, 2016
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…